Who Paid My Doc
Vaxneuvance
Biological Infectious Disease
NDC 0006-4329-03
General payments
$2,301,274
Research payments
$13,114
Through program year 2025, $2,301,274 in general payments and $13,114 in research payments were reported against Vaxneuvance (Infectious Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $379,812 | 18,965 |
| 2024 | General | $529,912 | 23,539 |
| 2024 | Research | $6,654 | 1 |
| 2023 | General | $838,349 | 33,091 |
| 2023 | Research | $6,460 | 1 |
| 2022 | General | $472,823 | 25,117 |
| 2021 | General | $80,378 | 5,092 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 127 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 53 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
105,804 general · 2 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.